April 17, 2012 Lancet Oncology Study Study shows significant side effect reduction with HIFU to treat prostate cancer... more >
Sky News, April 17, 2012 Prostate Cancer Treatment 'Reduces Side Effects' A high-powered beam of ultrasound can destroy prostate cancer without causing the serious side effects... more >
Urology Times, May 1, 2012 Data show low morbidity of HIFU in short-term trials Technique appears safe, but evaluation of efficacy awaits longer-term data... more >
High intensity
focused ultrasound, or HIFU, is a minimally invasive therapy
option for localised prostate cancer that may offer a balance
between eliminating cancer and maintaining quality of life.
The Sonablate® 500
(“Sonablate”) uses precisely focused ultrasound waves that,
when delivered, raise the temperature of the targeted
prostate tissue to 80-90 degrees Celsius in 2-3 seconds. This
rapid-firing heat destroys the targeted tissue while leaving
healthy structures outside the prostate gland unharmed.
UKHIFU, Limited (“UK HIFU”), a subsidiary of USHIFU, LLC, is the London-based
European distributor of the Sonablate medical device. UK HIFU is committed
to treating prostate cancer using HIFU with the Sonablate 500, a minimally
invasive, outpatient procedure pioneered to control cancer and significantly
improve patients’ quality of life. The Sonablate HIFU procedure is available
in almost 20 hospitals throughout the United Kingdom.
This website explores the Sonablate HIFU procedure for prostate cancer patients
located within the United Kingdom. Inside you will learn more about the procedure,
where it is available and if you qualify.
This
site complies to the